推荐产品
等級
pharmaceutical primary standard
API 家族
diclofenac
製造商/商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
[Na+].[O-]C(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl
InChI
1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1
InChI 密鑰
KPHWPUGNDIVLNH-UHFFFAOYSA-M
基因資訊
human ... PTGS1(5742) , PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
一般說明
双氯芬酸钠是一种非甾体抗炎药(NSAID)双氯芬酸的钠盐。它通过抑制环氧合酶活性来防止与疼痛、炎症和发烧有关的前列腺素的合成。
本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。
應用
双氯芬酸钠USP 参考标准品适用于指定USP 药典质量测试和分析。
还用于制备酸级标准(acid stage standard)、标准、标准储备、敏感性和系统适用性溶液,用于根据美国药典 (USP) 的以下专论,通过液相色谱和紫外检测器进行检测、杂质分析、鉴定和性能测试:
还用于制备酸级标准(acid stage standard)、标准、标准储备、敏感性和系统适用性溶液,用于根据美国药典 (USP) 的以下专论,通过液相色谱和紫外检测器进行检测、杂质分析、鉴定和性能测试:
- 双氯芬酸钠
- 双氯芬酸钠延迟释放片
- 双氯芬酸钠缓释片
- 双氯芬酸钠外用溶液
- 双氯芬酸钠和迷索前列醇延迟释放片
生化/生理作用
标准NSAID和环加氧酶(COX)抑制剂。主要代谢物是4′-羟基二苯甲酸和5′-羟基二氯芬酸。已被用作CYP2C9的选择性底物。
分析報告
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药,不可用于诊断、治疗或治愈任何疾病。
其他說明
可能适用相应的销售限制。
相關產品
产品编号
说明
价格
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Aquatic Chronic 2 - Repr. 2 - STOT RE 1
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
Adaptation of a color reaction for spectrophotometric determination of diclofenac sodium and piroxicam in pure form and in pharmaceutical formulations
Analytical Letters, 37(6), 1151-1162 (2004)
Drugs, 20(1), 24-48 (1980-07-01)
Diclofenac sodium, a phenylacetic acid derivative, is a non-steroidal, anti-inflammatory, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and allied conditions, and in the treatment of pain resulting from minor surgery, trauma and dysmenorrhoea. Published
Histology and histopathology, 27(4), 417-436 (2012-03-01)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the purpose of anti-inflammation, antipyretic, and analgesia. For this aim, they are used for the alleviation of pain, fever, and inflammation associated with rheumatoid arthritis, sports injuries, and temporary pain. However, treatment
Drugs, 68(1), 123-130 (2007-12-18)
*A new formulation of the nonselective NSAID diclofenac sodium suitable for intravenous bolus injection has been developed using hydroxypropyl beta-cyclodextrin as a solubility enhancer (HPbetaCD diclofenac). * HPbetaCD diclofenac intravenous bolus injection was shown to be bioequivalent to the existing
Clinical pharmacy, 8(8), 545-558 (1989-08-01)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of diclofenac sodium are reviewed. Diclofenac, the first nonsteroidal anti-inflammatory agent (NSAID) to be approved that is a phenylacetic acid derivative, competes with arachidonic acid for binding to cyclo-oxygenase, resulting in
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门